First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype

Table 3 Serum pepsinogen level and Helicobacter pylori eradication in the poor metabolizer group (CYP2C19 genotype: *2/*2, *2/*3, *3/*3)

Case	Age	Sex	CYP2C19 genotype	PG I/II				UBT	Eradication
				Before eradication		After eradication
P1	64	F	*2/*2	3.6	-	5.8	-	0.2	○
P2	46	M	*2/*2	4.0	-	5.5	-	1.2	○
P3	64	F	*2/*2	2.2	1+	3.8	-	1.1	○
P4	63	F	*2/*2	2.1	2+	3.9	-	0.0	○
P5	62	F	*2/*3	2.3	2+	4.2	-	0.2	○
P6	64	M	*2/*3	2.2	2+	5.0	-	0.0	○
P7	63	M	*2/*2	2.7	2+	4.9	-	1.2	○
P8	77	F	*3/*3	1.7	3+	2.9	2+	0.1	○
P9	68	M	*2/*2	1.3	2+	1.9	3+	1.2	○
P10	60	M	*2/*2	0.6	3+	1.4	3+	0.8	○
P11	57	M	*2/*2	4.1	-	ND	ND	0.2	○
P12	65	F	*2/*2	2.0	1+	2.0	1+	30.2	×
P13	38	F	*2/*2	2.3	2+	2.5	1+	63.8	×

(-), PG I ≥ 70 ng/mL and PG I/PG II ratio ≥ 3.0; (1+), PG I < 70 ng/mL and PG I/PG II ratio < 3.0; (2+), PG I < 50 ng/mL and PG I/PG II ratio < 3.0; (3+), PG I < 30 ng/mL and PG I/PG II ratio < 2.0. Eradication (○) rate = 11/13 (84.6%). M: Male; F: Female; ND: Not detected; PG: Pepsinogen; UBT: ¹³C-urea breath test.